Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of risdiplam after onasemnogene abeparvovec in young children with spinal muscular atrophy and stable or worsening function
MOH_2024-01-01_012942Phase 4Not yet recruiting
- Sponsor
- Roche
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of risdiplam in spinal muscular atrophy (SMA), sponsored by Roche. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on MOH_2024-01-01_012942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-01_012942.